• Profile
Close

Effects of selonsertib in patients with diabetic kidney disease

Journal of the American Society of Nephrology Sep 14, 2019

Chertow GM, et al. – In a cohort of adults with type 2 diabetes and treatment-refractory moderate-to-advanced diabetic kidney disease, researchers assessed the efficacy and safety of selonsertib. In this phase 2 trial, participants (n = 333) were randomized (1:1:1:1) to receive either selonsertib (oral daily doses of 2, 6, or 18 mg) or placebo. Change from baseline eGFR at 48 weeks was assessed as the primary outcome. According to findings, selonsertib demonstrated safe in this patient population, and no dose-dependent adverse effects were identified over 48 weeks. Although this trial did not meet its primary endpoint, the possible efficacy of selonsertib in slowing diabetic kidney disease progression was suggested in exploratory post hoc analyses performed in this study.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay